255 related articles for article (PubMed ID: 20298153)
1. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.
Karnak D; Xu L
Curr Drug Targets; 2010 Jun; 11(6):699-707. PubMed ID: 20298153
[TBL] [Abstract][Full Text] [Related]
2. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Li J; Viallet J; Haura EB
Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.
Finnegan NM; Curtin JF; Prevost G; Morgan B; Cotter TG
Br J Cancer; 2001 Jul; 85(1):115-21. PubMed ID: 11437412
[TBL] [Abstract][Full Text] [Related]
4. FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X
Maciel-Silva P; Caldeira I; de Assis Santos I; Carreira ACO; Siqueira FR; Antonioli E; Goldberg AC; Belizário JE; Garay-Malpartida HM
BMC Cancer; 2018 Jan; 18(1):90. PubMed ID: 29357840
[TBL] [Abstract][Full Text] [Related]
5. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
6. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
Sarosiek KA; Letai A
FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.
Rudner J; Elsaesser SJ; Müller AC; Belka C; Jendrossek V
Biochem Pharmacol; 2010 Jan; 79(1):10-20. PubMed ID: 19665451
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
9. The Role of BCL-2 Proteins in the Development of Castration-resistant Prostate Cancer and Emerging Therapeutic Strategies.
Soliman L; De Souza A; Srinivasan P; Danish M; Bertone P; El-Deiry WS; Carneiro BA
Am J Clin Oncol; 2021 Jul; 44(7):374-382. PubMed ID: 34014842
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
11. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
12. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
13. Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.
Dutta S; Ryan J; Chen TS; Kougentakis C; Letai A; Keating AE
J Mol Biol; 2015 Mar; 427(6 Pt B):1241-1253. PubMed ID: 25451027
[TBL] [Abstract][Full Text] [Related]
14. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.
Chaudhary KS; Abel PD; Lalani EN
Environ Health Perspect; 1999 Feb; 107 Suppl 1(Suppl 1):49-57. PubMed ID: 10229706
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
16. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
17. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.
Maji S; Panda S; Samal SK; Shriwas O; Rath R; Pellecchia M; Emdad L; Das SK; Fisher PB; Dash R
Adv Cancer Res; 2018; 137():37-75. PubMed ID: 29405977
[TBL] [Abstract][Full Text] [Related]
19. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
20. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
Peperzak V; Slinger E; Ter Burg J; Eldering E
Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
